Drug intelligence / Profile preview

BAY 1161116

Development stage: Discontinued
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

BAY 1161116 is an orally administered small molecule androgen receptor antagonist developed by Bayer. It specifically binds to the androgen receptor (AR), inhibits AR activation, and prevents AR-mediated signaling, thereby inhibiting cell proliferation in conditions where AR signaling is implicated. BAY 1161116 was investigated primarily for the treatment of polycystic ovary syndrome (PCOS). Clinical development included a first-in-human study evaluating its safety, tolerability, and pharmacokinetics. The drug's development has since been discontinued[1][2][3][4][7].

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on BAY 1161116.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAY 1161116.

Explore the full profile